Low Level Viremia Is Associated With Serious non-AIDS Events in People With HIV

被引:2
|
作者
Ganesan, Anuradha [1 ,2 ,3 ]
Hsieh, Hsing-Chuan [1 ,3 ]
Chu, Xiuping [1 ,3 ]
Colombo, Rhonda E. [1 ,3 ,4 ]
Berjohn, Catherine [1 ,5 ]
Lalani, Tahaniyat [1 ,3 ,6 ]
Yabes, Joseph [1 ,7 ]
Joya, Christie A. [1 ,6 ]
Blaylock, Jason [1 ,2 ]
Agan, Brian K. [1 ,2 ,3 ]
机构
[1] Uniformed Serv Univ Hlth Sci, Dept Prevent Med & Biostat, Infect Dis Clin Res Program, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA
[2] Walter Reed Natl Mil Med Ctr, Div Pediat Infect Dis, 8901 Wisconsin Ave,Bldg 7,Room 1416, Bethesda, MD 20889 USA
[3] Henry M Jackson Fdn Advancement Mil Med Inc, Bethesda, MD USA
[4] Madigan Army Med Ctr, Infect Dis Serv, Tacoma, WA 98431 USA
[5] Naval Med Ctr San Diego, Div Infect Dis, San Diego, CA USA
[6] Naval Med Ctr Portsmouth, Div Infect Dis, Portsmouth, VA USA
[7] Brooke Army Med Ctr, Div Infect Dis, San Antonio, TX USA
来源
OPEN FORUM INFECTIOUS DISEASES | 2024年 / 11卷 / 04期
基金
美国国家卫生研究院;
关键词
early treated; HIV; low- level viremia; military cohort; serious non-AIDS events; COMBINATION ANTIRETROVIRAL THERAPY; VIROLOGICAL OUTCOMES; ADHERENCE;
D O I
10.1093/ofid/ofae147
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The consequences of low-level viremia in people with HIV are unclear. We used data from the US Military HIV Natural History Study to examine the association of low-level viremia (LLV) and serious non-AIDS events (SNAEs). Methods. Included participants initiated antiretroviral therapy after 1996 and had >= 3 viral loads (VLs) measured, using an assay with a lower limit of detection of <50 copies/mL, >= 6 months after antiretroviral therapy initiation. VLs were categorized as lower levels of LLV (51-199 copies/mL), higher level of low-level viremia (HLLV; 200-999 copies/mL), and (VF; >= 200 copies/mL on 2 or more successive determinations or a single VL >= 1000 copies/mL), and virologic suppression (VS; ie, VL <50 copies/mL). Viral blips (ie, VLs between 50 and 999 copies/mL that are preceded and succeeded by VL <50 copies/mL) were analyzed in the VS category. Cox proportional hazards models were used to examine the association of LLV and SNAEs, adjusted hazard ratios and 95% confidence intervals are presented. Results. A total of 439 (17.4%) SNAEs were recorded among the 2528 participants (93% male, 40% Caucasian, 43% African American) followed for a median of 11 years. In 8.5% and 4.6% of the participants, respectively, LLV and HLLV were the highest recorded viremia strata. Compared with VS, SNAEs were associated with LLV (1.3 [1.2-1.4]), HLLV (1.6 [1.5-1.7]), and virologic failure (1.7 [1.7-1.8]). Conclusions. The results of this study suggest that LLV is associated with the occurrence of SNAEs and needs further study.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Associations between serum albumin and serious non-AIDS events among people living with HIV
    Ronit, Andreas
    Hatleberg, Camilla I.
    Ryom, Lene
    Bonnet, Fabrice
    El-Sadr, Wafaa
    Reiss, Peter
    Weber, Rainer
    Pradier, Christian
    De Wit, Stephane
    Law, Matthew
    Monforte, Antonella d'Arminio
    Lundgren, Jens
    Mocroft, Amanda
    Phillips, Andrew N.
    Sabin, Caroline A.
    [J]. AIDS, 2018, 32 (13) : 1837 - 1848
  • [2] Development of Diagnostic Criteria for Serious Non-AIDS Events in HIV Clinical Trials
    Lifson, Alan R.
    Belloso, Waldo H.
    Davey, Richard T.
    Duprez, Daniel
    Gatell, Jose M.
    Hoy, Jennifer F.
    Krum, Eric A.
    Nelson, Ray
    Pedersen, Court
    Perez, George
    Price, Richard W.
    Prineas, Ronald J.
    Rhame, Frank S.
    Sampson, James H.
    Worley, John
    [J]. HIV CLINICAL TRIALS, 2010, 11 (04): : 205 - 219
  • [3] Serious Non-AIDS events: Immunopathogenesis and interventional strategies
    Denise C Hsu
    Irini Sereti
    Jintanat Ananworanich
    [J]. AIDS Research and Therapy, 10
  • [4] Serious Non-AIDS events: Immunopathogenesis and interventional strategies
    Hsu, Denise C.
    Sereti, Irini
    Ananworanich, Jintanat
    [J]. AIDS RESEARCH AND THERAPY, 2013, 10
  • [5] Risk of all-cause mortality associated with nonfatal AIDS and serious non-AIDS events among adults infected with HIV
    Neuhaus, Jacqueline
    Angus, Brian
    Kowalska, Justyna D.
    La Rosa, Alberto
    Sampson, Jim
    Wentworth, Deborah
    Mocroft, Amanda
    [J]. AIDS, 2010, 24 (05) : 697 - 706
  • [6] Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection
    Denise C. Hsu
    Irini Sereti
    [J]. Drugs, 2016, 76 : 533 - 549
  • [7] Emerging Role and Characterization of Immunometabolism: Relevance to HIV Pathogenesis, Serious Non-AIDS Events, and a Cure
    Palmer, Clovis S.
    Henstridge, Darren C.
    Yu, Di
    Singh, Amit
    Balderson, Brad
    Duette, Gabriel
    Cherry, Catherine L.
    Anzinger, Joshua J.
    Ostrowski, Matias
    Crowe, Suzanne M.
    [J]. JOURNAL OF IMMUNOLOGY, 2016, 196 (11): : 4437 - 4444
  • [8] Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection
    Hsu, Denise C.
    Sereti, Irini
    [J]. DRUGS, 2016, 76 (05) : 533 - 549
  • [9] Serious Non-AIDS Conditions in HIV: Benefit of Early ART
    Jens D. Lundgren
    Alvaro H. Borges
    James D. Neaton
    [J]. Current HIV/AIDS Reports, 2018, 15 : 162 - 171
  • [10] Serious Non-AIDS Conditions in HIV: Benefit of Early ART
    Lundgren, Jens D.
    Borges, Alvaro H.
    Neaton, James D.
    [J]. CURRENT HIV/AIDS REPORTS, 2018, 15 (02) : 162 - 171